Electromed Presents Growth Plan to Investors After Annual Revenue Rises 15.3%
Key Facts
Electromed presented its growth and profitability plans at the LD Micro conference on October 20, 2026, after annual revenue rose 15.3%, according to Investing.com and company disclosures. Revenue reached a record $73.8 million in the fiscal year ended June 2026. The company had reported revenue of $64.0 million in fiscal 2025, according to its earnings release filed with the U.S. Securities and Exchange Commission. Its strategy places growth in its home care business at the heart of its expansion plans through a larger sales force, market development and payer contracts. Its investor presentation also includes exploring potential acquisitions alongside expanding its existing business.
Results for the fiscal fourth quarter ended June 2026 showed revenue rising 11.6% to $19.4 million from $17.4 million in the same period a year earlier. For the fiscal year, operating income totaled $13.9 million, according to the company's investor presentation. The operating margin was 18.8%, while net income totaled $11.3 million. Diluted earnings per share reached $1.30 for the same fiscal year. Cash generated from operations, however, fell to $9.7 million from $11.4 million in the previous fiscal year, according to the earnings release.
The annual gross profit margin reached a company record of 78.5%, according to its annual report. Electromed attributed improved operating leverage to operating expenses growing more slowly than revenue. It said in the report that "operating expenses grew at a slower rate than revenue." Its business model relies on selling directly to patients, according to the company's description of its operations in the annual report. This approach allows it to retain both manufacturing and distribution margins, one of the sources of profitability it cited in explaining its business economics.
On commercial expansion, Electromed ended the fiscal year with a direct sales force of 64 representatives, according to its annual report. This included hires made ahead of planned expansion in the sales territories the company covers. Electromed estimated the U.S. revenue opportunity for bronchiectasis treatment at about $3.1 billion, according to its August 2026 investor presentation. The estimate relates to treatment using high-frequency chest wall oscillation technology. It covers patients under the care of pulmonologists within the company's commercial target market in the United States.
Alongside expanding sales, the company signed 40 new contracts with healthcare payers during fiscal 2026. These agreements increased its contracted coverage to more than 87% of covered lives in the United States, according to the annual report. Electromed lists the ability to obtain reimbursement among the risks that could affect its performance. The payers it names in this context include Medicare, Medicaid and private insurers. It also lists continued access to reimbursement among its business risks, alongside the ability to secure it in the first place.
The presentation of its growth plans comes as the company prepares for the succession of Jim Cunniff, who has served as president, chief executive officer and a board member since 2023. The company disclosed his retirement plan on August 25, 2026, ahead of its participation in the conference. The board retained an executive search firm to select the next CEO, according to the SEC filing. Electromed is scheduled to hold its annual shareholder meeting virtually on November 13, 2026, allowing shareholders to put questions to management. The company expects Cunniff to retire around April 2, 2027, when he will also resign from the board.